Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: xomadog2 who wrote (9008)	3/8/1999 10:46:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Note the standard of care in the UK. Examine it wisely.>>>>>>>>>>> >>>>>>>>>> >http://www.archdischild.com/cgi/content/full/archdischild;80/3/290

To: xomadog2 who wrote (9008)	3/9/1999 10:00:00 AM
From: Chris Boylan	Respond to of 17367

> I believe that you are missing the point.The primary endpoint > of this trial is mortality,not morbidity. Sorry I wrote that in haste. Obviously I meant mortality not morbidity in my original post. If you will reread my original post I think you will agree (or at least you should) that extending the trial twice to increase the number of deaths included is best interpreted as meaning that they have been unable to get usable results despite a lower standard of statistical significance set by the FDA. Recall that originally they were going to enroll about 260 patients.

To: xomadog2 who wrote (9008)	3/9/1999 1:14:00 PM
From: Thomas J Pittman	Read Replies (2) \| Respond to of 17367

Isnt the point that people have to die since the assumption is that when we unblind the results we will see a large statistically significant difference in the numbers of those who died on the placebo and those who died on newprex? If only three died and two died on the placebo and one died on the drug, i guess the fda could conclude 1) that the disease can currently be adequately treated with existing technologies since people are dying or 2) that there wasnt enough difference in treatment/nontreatment to justify a new drug. But God help them if they unblind it and find that there were no deaths on the drug and yet the trial was allowed to continue with sick kids getting sugar pills. I am probably just slow on the uptake. Maybe all of this is obvious to everyone else. Or maybe its wrong. Maybe I am just so eager for these guys to get something right so I can take my money and go home. J